CAMBRIDGE, Mass., April 18, 2019 – BlueRock Therapeutics, LP, an engineered cell therapy company leveraging its novel CELL+GENE™ platform to develop regenerative medicines for intractable diseases, today announced its participation in the inaugural Cell & Gene Meeting on the Mediterranean to be held April 23-25 in Barcelona, Spain.
Emile Nuwaysir, Ph.D., President and Chief Executive Officer of BlueRock, and Vice Chairman of the Alliance for Regenerative Medicine (ARM), will be speaking at the conference. BlueRock is using its unique CELL+GENE platform to direct cellular differentiation and genetically engineer cells to create an entirely new generation of cellular medicines in the areas of neurology, cardiology and immunology.
The following are specific details regarding BlueRock’s participation at the conference:
Date: Tuesday, April 23, 2019
Time: 2:15 p.m. CEST / 8:15 a.m. EDT
Location: Meeting Room Gaudí 2, Hotel Arts Barcelona, Marina 19-21, 08005 Barcelona, Spain
A live video webcast of the company presentation will be available at: http://www.meetingonthemed.com/webcast and will also be published on the conference website shortly after the event.
Organized by the Alliance for Regenerative Medicine, the Cell & Gene Meeting on the Mediterranean will bring together the entire cell and gene therapy community from Europe and beyond. Covering a wide range of commercialization topics from market access and regulatory issues to manufacturing and financing the sector, the program will feature expert-led panels, extensive one-on-one partnering capabilities and exclusive networking opportunities.
About BlueRock Therapeutics
BlueRock Therapeutics is an engineered cell therapy company with a mission to develop regenerative medicines for intractable diseases. BlueRock’s CELL+GENE™ platform harnesses the power of cells for new medicines across neurology, cardiology and immunology. BlueRock’s cell differentiation technology recapitulates the cell’s developmental biology to produce native cell therapies which are further engineered for additional function. Utilizing these cell therapies to replace damaged or degenerated tissue brings the potential to restore or regenerate lost function. BlueRock was founded in 2016 by Versant Ventures and capitalized with one of the largest-ever Series A financings in biotech history by Bayer AG and Versant. BlueRock’s culture is defined by scientific innovation, highest ethical standards and an urgency to bring transformative treatments to all who would benefit. For more information, visit www.bluerocktx.com.
Candice Ellis, 978-879-7273
Associate Director, Investor Relations and Corporate Communications
David Schull or Maggie Beller Russo Partners, LLC